Ion Beam Applications Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Olivier Legrain

Chief executive officer

€815.9k

Total compensation

CEO salary percentage	51.7%
CEO tenure	12.1yrs
CEO ownership	n/a
Management average tenure	12.1yrs
Board average tenure	10.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Olivier Legrain's remuneration changed compared to Ion Beam Applications's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€816k	€422k	-€9m
Sep 30 2023	n/a	n/a	-€14m
Jun 30 2023	n/a	n/a	-€19m
Mar 31 2023	n/a	n/a	-€7m
Dec 31 2022	€880k	€412k	€6m
Sep 30 2022	n/a	n/a	€5m
Jun 30 2022	n/a	n/a	€4m
Mar 31 2022	n/a	n/a	€4m
Dec 31 2021	€885k	€391k	€4m
Sep 30 2021	n/a	n/a	€23m
Jun 30 2021	n/a	n/a	€42m
Mar 31 2021	n/a	n/a	€37m
Dec 31 2020	€768k	€389k	€32m
Sep 30 2020	n/a	n/a	€16m
Jun 30 2020	n/a	n/a	€884k
Mar 31 2020	n/a	n/a	€4m
Dec 31 2019	€575k	€386k	€8m
Sep 30 2019	n/a	n/a	€5m
Jun 30 2019	n/a	n/a	-€2m
Mar 31 2019	n/a	n/a	-€3m
Jan 01 2019	n/a	n/a	-€4m
Sep 30 2018	n/a	n/a	-€25m
Jun 30 2018	n/a	n/a	-€45m
Mar 31 2018	n/a	n/a	-€43m
Dec 31 2017	€758k	€371k	-€42m

Compensation vs Market: Olivier's total compensation ($USD871.40K) is about average for companies of similar size in the German market ($USD1.07M).

Compensation vs Earnings: Olivier's compensation has been consistent with company performance over the past year.

CEO

Olivier Legrain (56 yo)

12.1yrs

Tenure

€815,891

Compensation

Mr. Olivier Legrain has been the Chief Executive Officer and Executive Director at Ion Beam Applications, S.A. since May 9, 2012 and served as its President of Molecular Medicine. He served as President at...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pierre Mottet	Chairman of The Board	26.1yrs	€61.50k	no data
Olivier Legrain	CEO, MD & Executive Director	12.1yrs	€815.89k	no data
Yves Jongen	Founder	no data	€564.08k	no data
Soumya Chandramouli	Chief Financial Officer	8yrs	no data	no data
Frederic Nolf	Chief Human Resources & Sustainability Officer	14.4yrs	no data	no data
Marc Van der Burght	Chief Operation Officer	no data	no data	no data
Olivier Lechien	Corporate Communication Director	no data	no data	no data
Thomas Canon	Sustainability Program Director	no data	no data	no data
Bruno Scutnaire	President of IBA RadioPharma Solutions	no data	no data	no data

12.1yrs

Average Tenure

56yo

Average Age

Experienced Management: IOB's management team is seasoned and experienced (12.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pierre Mottet	Chairman of The Board	26.1yrs	€61.50k	no data
Olivier Legrain	CEO, MD & Executive Director	12.1yrs	€815.89k	no data
Yves Jongen	Founder	33.1yrs	€564.08k	no data
Marcel Miller	Independent Director	13.1yrs	€34.00k	no data
Richard Hausmann	Independent Director	3.8yrs	€32.40k	no data
Sybille van den Hove	Independent Director	9.1yrs	€26.40k	no data
Hedvig Hricak	Independent Director	7.1yrs	€32.00k	no data
Christine Dubus	Independent Director	3.8yrs	€39.40k	no data

10.6yrs

Average Tenure

64yo

Average Age

Experienced Board: IOB's board of directors are seasoned and experienced ( 10.6 years average tenure).

Ion Beam Applications Management

Management criteria checks 4/4

Key information

Recent management updates

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Insufficient new directors

Recent updates

Dividend of €0.12 announced

Full year 2023 earnings released: €0.31 loss per share (vs €0.21 profit in FY 2022)

New minor risk - Share price stability

Full year 2023 earnings released

Ion Beam Applications SA to Report First Half, 2024 Results on Aug 29, 2024

Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Ion Beam Applications S.A Plans Total System Restoration on its First-Ever Proton Therapy Installation

Insufficient new directors

New minor risk - Dividend sustainability

Full year 2022 earnings released

Ion Beam Applications SA to Report Q1, 2023 Results on May 18, 2023

First half 2022 earnings released: €0.059 loss per share (vs €0.066 loss in 1H 2021)

Ion Beam Applications SA Continues to Shape the Future of Proton Therapy At Estro 2022 Annual Congress

Ion Beam Applications SA (ENXTBR:IBAB) acquired Modus Medical Devices Inc.

Full year 2021 earnings released: EPS: €0.13 (vs €1.08 in FY 2020)

Investor sentiment improved over the past week

IBA Launches Compact Low-Energy Cyclotron, Cyclone® KEY

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released

Ion Beam Applications S.A. Announces Launch of a Large-Scale, Multi-Institutional, Randomized Controlled Clinical Trial

Full year 2020 earnings released

IBA (Ion Beam Applications S.A. and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

Ion Beam Applications SA Receives Down Payment from National Cancer Center Korea for A Second Proteus® System

Ion Beam Applications SA to Report Q3, 2021 Results on Nov 18, 2021

New 90-day high: €13.36

New 90-day high: €13.26

New 90-day high: €12.00

New 90-day high: €11.58

Ion Beam Applications SA Signs Contract for the First End-To-End Rhodotron® Duo Solution for Multi-Purpose Irradiation in Taiwan

Ion Beam Applications SA Announces First Payment of EUR 20 Million Received for Strategic Licensing Deal in China

New 90-day high: €10.50

Ion Beam Applications SA to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day low - €7.10

New 90-day high - €8.39

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age